EP 4110405 A1 20230104 - ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY
Title (en)
ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY
Title (de)
ANTI-CD56-ANTIKÖRPER-WIRKSTOFF-KONJUGATE UND IHRE VERWENDUNG IN DER THERAPIE
Title (fr)
CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-CD56 ET LEUR UTILISATION EN THÉRAPIE
Publication
Application
Priority
- FR 2001974 A 20200227
- FR 2021050332 W 20210226
Abstract (en)
[origin: WO2021170961A1] The invention relates to antibody-drug conjugates and to their use in therapy, in particular for treating CD56+ cancers.
IPC 8 full level
A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC (source: EP US)
A61K 31/40 (2013.01 - US); A61K 47/68031 (2023.08 - EP); A61K 47/6849 (2017.08 - EP US); A61K 47/6865 (2017.08 - EP); A61K 47/6889 (2017.08 - EP); A61P 35/00 (2018.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021170961 A1 20210902; AU 2021227413 A1 20221020; CA 3166699 A1 20210902; CN 115515642 A 20221223; EP 4110405 A1 20230104; FR 3107648 A1 20210903; FR 3107648 B1 20220318; JP 2023515845 A 20230414; US 2023144142 A1 20230511; US 2023405140 A1 20231221
DOCDB simple family (application)
FR 2021050332 W 20210226; AU 2021227413 A 20210226; CA 3166699 A 20210226; CN 202180017269 A 20210226; EP 21714002 A 20210226; FR 2001974 A 20200227; JP 2022552310 A 20210226; US 202117802274 A 20210226; US 202318333261 A 20230612